Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Wu S, Bai X, Guo C, Huang Z, Ouyang H, Huang J, Zeng W
Zepbound (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
Rybelsus 3 mg Tablet - Summary of Product Characteristics
Pharmaceutical Profiling in Drug Discovery for Lead Selection
ADA: Lilly makes its case for oral GLP-1 orforglipron A first look at the phase 3 data with Eli Lilly's oral GLP-1 agonist orforglipron reveals encouraging blood sugar control data in patients with type 2 diabetes, and a side-effect profile free of the liver toxicity that scuppered rival candidates from Pfizer
These arent new compounds (the first GLP-1 was approved in 2005), but the newest versions are far more powerful
